Please use this identifier to cite or link to this item:
|Scopus||Web of Science®|
|Title:||Status of clomiphene citrate and metformin for infertility in PCOS|
|Citation:||Trends in Endocrinology and Metabolism, 2012; 23(10):533-543|
|Publisher:||Elsevier Science London|
|Marie L. Misso, Helena J. Teede, Roger Hart, Jennifer Wong, Luk Rombauts, Angela M. Melder, Robert J. Norman and Michael F. Costello|
|Abstract:||Though widely used, there is uncertainty about the effectiveness and adverse effects of metformin and clomiphene citrate (CC) for infertility in polycystic ovary syndrome (PCOS). A systematic review (SR) of the best available evidence suggests that both CC and metformin are better than placebo for increasing ovulation and pregnancy rates, but CC is more effective than metformin for ovulation, pregnancy and live-birth rates, in PCOS patients with body mass index (BMI) >30. A combination of CC and metformin is superior to either metformin alone or CC alone, depending on the BMI and CC sensitivity of the patient. This SR provides key messages to guide clinicians and consumers on the use of these interventions in different subgroups of women with PCOS.|
|Keywords:||Humans; Polycystic Ovary Syndrome; Infertility, Female; Metformin; Clomiphene; Ovulation Induction; Female|
|Rights:||© 2012 Elsevier Ltd. All rights reserved.|
|Appears in Collections:||Medical Sciences publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.